How This Works
Vilon belongs to a class of short bioregulatory peptides developed through Russian gerontology research[4]. In vitro studies demonstrate that the Lys‑Glu dipeptide can modulate lymphocyte populations and cytokine gene expression. Specifically, Vilon has been observed to increase CD5+ cell counts in thymus cell cultures[1] and upregulate interleukin‑2 (IL‑2) mRNA expression in splenocyte preparations[2]. Additional preclinical work suggests effects on TGF‑β1 and vascular permeability in renal models[3]. The pulsed 5‑day monthly regimen is analogized from related short peptide protocols such as Epitalon[5].
References
Sevostianova NN et al. (2013)
— Immunomodulating effects of Vilon and its analogue in the culture of human and animal thymus cells
Kazakova TB et al. (2002)
— In vitro effect of short peptides on expression of interleukin‑2 gene in splenocytes
Gavrisheva NA et al. (2005)
— Effect of Vilon peptide on TGF‑β1 and vascular permeability in chronic renal failure
Kniaz’kin IA et al. (2002)
— Effect of a peptide Vilon on immune aging (Adv Gerontol)
Araj SK et al. (2025)
— Overview of Epitalon—highly bioactive pineal tetrapeptide with promising properties (Int J Mol Sci)
Chernyak EY et al. (2000)
— Synthetic dipeptide Vilon inhibits tumor growth and prolongs life in mice (Dokl Biol Sci)
Avolio F et al. (2022)
— Peptides regulating proliferative activity and inflammatory pathways in THP‑1 macrophages (Int J Mol Sci)
Wong AKC et al. (2024)
— Measurement techniques to reduce heparin complications (J Adv Nurs)
MedlinePlus (NIH)
— (SQ) measurements: research sample information
Merck KGaA (Millipore Sigma)
— Handling and storage guidelines for peptides and proteins
CDC
— Vaccine preparation: route (angle/site; no aspiration)
NCBI Bookshelf
— Best practices for measurement (asepsis, preparation, and preparation)
